Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
This model could provide early prediction of PFS outcomes, which otherwise takes lengthy periods of time to observe in clinical trials. Patients showing rapid rebound from low MRD values may benefit from adding another treatment before reaching progressive disease. The MRD analyses and results presented, such as the results about efficacy occurring early in the first 6 to 12 months, may help guide the development and selection of optimal regimens. Longer follow-up periods and application to other trials and datasets are required to substantiate these findings.
Authors
- Pieter Sonneveld (ORCID: https://orcid.org/0000-0002-0808-2237)
- Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
- Walter M. Gregory (ORCID: https://orcid.org/0000-0003-2641-8416)
- Thierry T.F. Facon (ORCID: https://orcid.org/0000-0001-7705-8460)
- Meletios Athanasios Dimopoulos (ORCID: https://orcid.org/0000-0001-8990-3254)
- Thomas J. Prior (ORCID: https://orcid.org/0000-0001-5220-7730)
- JB Bartlett
- Philippe Moreau (ORCID: https://orcid.org/0000-0003-1780-8746)
Institutions
- Johnson & Johnson (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- National and Kapodistrian University of Athens (GR)
- Université de Lille (FR)
- Hotel Dieu Hospital (CA)
- Erasmus MC (NL)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Kettering University (US)
- Springhouse (US)
- Alexandra Hospital (GR)
- Erasmus MC Cancer Institute (NL)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
- University of Sheffield (GB)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3475
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77